IBDEI15H ; ; 06-AUG-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,20298,0)
 ;;=446.5^^107^1255^47
 ;;^UTILITY(U,$J,358.3,20298,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,20298,1,4,0)
 ;;=4^Giant Cell Arteritis
 ;;^UTILITY(U,$J,358.3,20298,1,5,0)
 ;;=5^446.5
 ;;^UTILITY(U,$J,358.3,20298,2)
 ;;=^117658
 ;;^UTILITY(U,$J,358.3,20299,0)
 ;;=446.21^^107^1255^48
 ;;^UTILITY(U,$J,358.3,20299,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,20299,1,4,0)
 ;;=4^Goodpasture's Syndrome
 ;;^UTILITY(U,$J,358.3,20299,1,5,0)
 ;;=5^446.21
 ;;^UTILITY(U,$J,358.3,20299,2)
 ;;=^52601
 ;;^UTILITY(U,$J,358.3,20300,0)
 ;;=V58.67^^107^1255^56
 ;;^UTILITY(U,$J,358.3,20300,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,20300,1,4,0)
 ;;=4^Long-Term Use of Insulin
 ;;^UTILITY(U,$J,358.3,20300,1,5,0)
 ;;=5^V58.67
 ;;^UTILITY(U,$J,358.3,20300,2)
 ;;=^331585
 ;;^UTILITY(U,$J,358.3,20301,0)
 ;;=446.1^^107^1255^60
 ;;^UTILITY(U,$J,358.3,20301,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,20301,1,4,0)
 ;;=4^Mucocutan Lymph Node Syndrome
 ;;^UTILITY(U,$J,358.3,20301,1,5,0)
 ;;=5^446.1
 ;;^UTILITY(U,$J,358.3,20301,2)
 ;;=^79494
 ;;^UTILITY(U,$J,358.3,20302,0)
 ;;=433.30^^107^1255^63
 ;;^UTILITY(U,$J,358.3,20302,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,20302,1,4,0)
 ;;=4^Occl/Sten Mult/Bil Art w/o CRB
 ;;^UTILITY(U,$J,358.3,20302,1,5,0)
 ;;=5^433.30
 ;;^UTILITY(U,$J,358.3,20302,2)
 ;;=^295803
 ;;^UTILITY(U,$J,358.3,20303,0)
 ;;=451.83^^107^1255^69
 ;;^UTILITY(U,$J,358.3,20303,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,20303,1,4,0)
 ;;=4^Phl/Thrombophl Deep Veins,UEs
 ;;^UTILITY(U,$J,358.3,20303,1,5,0)
 ;;=5^451.83
 ;;^UTILITY(U,$J,358.3,20303,2)
 ;;=^295745
 ;;^UTILITY(U,$J,358.3,20304,0)
 ;;=451.82^^107^1255^70
 ;;^UTILITY(U,$J,358.3,20304,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,20304,1,4,0)
 ;;=4^Phl/Thrombophl Sup Veins,UEs
 ;;^UTILITY(U,$J,358.3,20304,1,5,0)
 ;;=5^451.82
 ;;^UTILITY(U,$J,358.3,20304,2)
 ;;=^295744
 ;;^UTILITY(U,$J,358.3,20305,0)
 ;;=451.84^^107^1255^71
 ;;^UTILITY(U,$J,358.3,20305,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,20305,1,4,0)
 ;;=4^Phl/Thrombophl,UEs,Unspec
 ;;^UTILITY(U,$J,358.3,20305,1,5,0)
 ;;=5^451.84
 ;;^UTILITY(U,$J,358.3,20305,2)
 ;;=^295746
 ;;^UTILITY(U,$J,358.3,20306,0)
 ;;=446.0^^107^1255^73
 ;;^UTILITY(U,$J,358.3,20306,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,20306,1,4,0)
 ;;=4^Polyartertitis Nodosa
 ;;^UTILITY(U,$J,358.3,20306,1,5,0)
 ;;=5^446.0
 ;;^UTILITY(U,$J,358.3,20306,2)
 ;;=^91874
 ;;^UTILITY(U,$J,358.3,20307,0)
 ;;=V81.0^^107^1255^77
 ;;^UTILITY(U,$J,358.3,20307,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,20307,1,4,0)
 ;;=4^Screen for Ischemic Heart Disease
 ;;^UTILITY(U,$J,358.3,20307,1,5,0)
 ;;=5^V81.0
 ;;^UTILITY(U,$J,358.3,20307,2)
 ;;=^295687
 ;;^UTILITY(U,$J,358.3,20308,0)
 ;;=353.0^^107^1255^84
 ;;^UTILITY(U,$J,358.3,20308,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,20308,1,4,0)
 ;;=4^Thoracic Outlet Syndrome
 ;;^UTILITY(U,$J,358.3,20308,1,5,0)
 ;;=5^353.0
 ;;^UTILITY(U,$J,358.3,20308,2)
 ;;=^16605
 ;;^UTILITY(U,$J,358.3,20309,0)
 ;;=451.89^^107^1255^87
 ;;^UTILITY(U,$J,358.3,20309,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,20309,1,4,0)
 ;;=4^Thrombophlebitis NEC
 ;;^UTILITY(U,$J,358.3,20309,1,5,0)
 ;;=5^451.89
 ;;^UTILITY(U,$J,358.3,20309,2)
 ;;=^176957
 ;;^UTILITY(U,$J,358.3,20310,0)
 ;;=451.9^^107^1255^88
 ;;^UTILITY(U,$J,358.3,20310,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,20310,1,4,0)
 ;;=4^Thrombophlebitis NOS
 ;;^UTILITY(U,$J,358.3,20310,1,5,0)
 ;;=5^451.9
 ;;^UTILITY(U,$J,358.3,20310,2)
 ;;=^93357
 ;;^UTILITY(U,$J,358.3,20311,0)
 ;;=707.13^^107^1255^93
 ;;^UTILITY(U,$J,358.3,20311,1,0)
 ;;=^358.31IA^5^2
 ;;
 ;;$END ROU IBDEI15H
